VETO.F Stock Overview

A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. More details

VETO.F fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	2/6
Financial Health	5/6
Dividends	3/6

Rewards

Trading at 47.7% below our estimate of its fair value

Earnings are forecast to grow 7.46% per year

Analysts in good agreement that stock price will rise by 26.8%

Risk Analysis

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Vetoquinol SA Competitors

Phibro Animal Health

NasdaqGM:PAHC

US$995.6m

Innoviva

NasdaqGS:INVA

US$1.1b

Collegium Pharmaceutical

NasdaqGS:COLL

US$998.1m

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$2.1b

Price History & Performance

Summary of share price highs, lows and changes for Vetoquinol
Historical stock prices
Current Share Price	€72.04
52 Week High	€72.04
52 Week Low	€72.04
Beta	0.90
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	126.90%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	VETO.F	US Pharmaceuticals	US Market
7D	0%	0.2%	0.2%
1Y	n/a	1.3%	22.0%

Return vs Industry: Insufficient data to determine how VETO.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how VETO.F performed against the US Market.

Price Volatility

Is VETO.F's price volatile compared to industry and market?
VETO.F volatility
VETO.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.1%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: VETO.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine VETO.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1933	2,519	Matthieu Frechin	www.vetoquinol.com

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France.

Vetoquinol SA Fundamentals Summary

How do Vetoquinol's earnings and revenue compare to its market cap?
VETO.F fundamental statistics
Market cap	US$905.84m
Earnings (TTM)	US$48.97m
Revenue (TTM)	US$558.29m

18.5x

P/E Ratio

1.6x

P/S Ratio

Is VETO.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VETO.F income statement (TTM)
Revenue	€537.47m
Cost of Revenue	€250.03m
Gross Profit	€287.44m
Other Expenses	€240.30m
Earnings	€47.14m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Mar 20, 2025

Earnings per share (EPS)	3.98
Gross Margin	53.48%
Net Profit Margin	8.77%
Debt/Equity Ratio	1.2%

How did VETO.F perform over the long term?

See historical performance and comparison

Dividends

1.2%

Current Dividend Yield

21%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/07 21:54
End of Day Share Price	2025/01/30 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vetoquinol SA is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Carole Rozen	CA Cheuvreux
Arnaud Cadart	CIC Market Solutions (ESN)
Alexandre Letz	Gilbert Dupont